Blood Cancer Is a Broad Term. Here's What It Includes
recurrent endometrial cancer in lungs :: Article Creator Imfinzi Fails Lung Cancer Trial, But Scores In Bladder Cancer AstraZeneca's hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder cancer study. Top-line results from the phase 3 ADJUVANT BR.31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS). The trial enrolled patients with NSCLC that had PD-L1 expression on 25% or more cells whose tumours had been completely removed with surgery. Imfinzi is already approved for unresectable, stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy (CRT), based on the results of the PACIFIC trial, carving out a niche for itself away from the dominance of MSD's K...